Skip to main content
SpringerLink
Log in

New Formulations of Stimulants for Attention-Deficit Hyperactivity Disorder

Therapeutic Potential

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

New formulations of stimulant medications for the treatment of attention-deficit hyperactivity disorder (ADHD) have been an important focus for pharmaceutical industry research and development over the past decade. In this article, we review and assess the therapeutic potential of five new stimulant formulations (one immediate release and four longer-acting preparations) that have recently become available for the treatment of ADHD.

While the therapeutic potential of immediate-release enantiomers of methyl-phenidate has not yet been clinically realised, new long-acting formulations of stimulants have changed the standard of care for children, adolescents and adults with ADHD. The longer duration of action of these once-daily compounds, and the consequent expansion of the duration of daily ADHD coverage afforded by them, has introduced the realistic possibility of reducing the overall daily burden of ADHD on affected individuals. Although more expensive, these new stimulant formulations are easier for patients to use than older stimulants, more resistant to abuse and misuse, and allow for increased privacy of ADHD treatment at school or work.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Table III
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th rev. ed. Washington, DC: American Psychiatric Press, 1994

    Google Scholar 

  2. Barkley RA. International consensus statement on ADHD. Clin Child Fam Psychol Rev 2002; 5: 89–111

    Article  PubMed  Google Scholar 

  3. Brown RT, Freeman WS, Perrin JM, et al. Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings. Pediatrics 2001; 107(3): e43

    Article  PubMed  CAS  Google Scholar 

  4. Hinshaw SP. Attention deficits and hyperactivity in children. Thousand Oaks (CA): Sage, 1994

    Google Scholar 

  5. US Department of Health and Human Services. Mental health: a report of the Surgeon General. Washington, DC: US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, National Institutes of Health, National Institute of Mental Health, 1999

    Google Scholar 

  6. American Academy of Pediatrics. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyper-activity disorder. Pediatrics 2001; 108: 1033–44

    Article  Google Scholar 

  7. Barkley RA. Attention-deficit hyperactivity disorder. Sci Am 1998; 279: 66–71

    Article  PubMed  CAS  Google Scholar 

  8. Anderson JC, Williams S, McGee R, et al. DSM-III disorders in preadolescent children: prevalence in a large sample from the general population. Arch Gen Psychiatry 1987; 44: 69–76

    Article  PubMed  CAS  Google Scholar 

  9. Fergusson DM, Horwood LJ, Lynskey MT. Prevalence and comorbidity of DSM-III-R diagnoses in a birth cohort of 15 year olds. J Am Acad Child Adolesc Psychiatry 1993; 32: 1127–34

    Article  PubMed  CAS  Google Scholar 

  10. McGee R, Feehan M, Williams S, et al. DSM-III disorders in a large sample of adolescents. J Am Acad Child Adolesc Psychiatry 1990; 29: 611–9

    Article  PubMed  CAS  Google Scholar 

  11. Bird HR, Canino G, Rubio-Stipec M, et al. Estimates of the prevalence of childhood maladjustment in a community survey in Puerto Rico. Arch Gen Psychiatry 1988; 45: 1120–6

    Article  PubMed  CAS  Google Scholar 

  12. Rohde LA. ADHD in Brazil: the DSM-IV criteria in a culturally different population. J Am Acad Child Adolesc Psychiatry 2002; 41: 1131–3

    Article  PubMed  Google Scholar 

  13. Rohde LA, Biederman J, Busnello EA, et al. ADHD in a school sample of Brazilian adolescents: a study of prevalence, comorbid conditions, and impairments. J Am Acad Child Adolesc Psychiatry 1999; 38: 716–22

    Article  PubMed  CAS  Google Scholar 

  14. Baumgaertel A, Wolraich ML, Dietrich M. Comparison of diagnostic criteria for attention deficit disorders in a German elementary school sample. J Am Acad Child Adolesc Psychiatry 1995; 34: 629–38

    Article  PubMed  CAS  Google Scholar 

  15. Esser G, Schmidt MH, Woerner W. Epidemiology and course of psychiatric disorders in school-age children: results of a longitudinal study. J Child Psychol Psychiatry 1990; 31: 243–63

    Article  PubMed  CAS  Google Scholar 

  16. Bhatia MS, Nigam VR, Bohra N, et al. Attention deficit disorder with hyperactivity among paediatric outpatients. J Child Psychol Psychiatry 1991; 32: 297–306

    Article  PubMed  CAS  Google Scholar 

  17. Leung PWL, Luk SL, Ho TP, et al. The diagnosis and prevalence of hyperactivity in Chinese schoolboys. Br J Psychiatry 1996; 168: 486–96

    Article  PubMed  CAS  Google Scholar 

  18. Kanbayashi Y, Nakata Y, Fujii K, et al. ADHD-related behavior among non-referred children: parents’ ratings of DSM-III-R symptoms. Child Psychiatry Hum Dev 1994; 25: 13–29

    Article  PubMed  CAS  Google Scholar 

  19. Gadow KD, Nolan EE, Litcher L, et al. Comparison of attention-deficit/hyperactivity disorder symptom subtypes in Ukrainian schoolchildren. J Am Acad Child Adolesc Psychiatry 2000; 39: 1520–7

    Article  PubMed  CAS  Google Scholar 

  20. Verhulst FC, van der Ende J, Ferdinand RF, et al. The prevalence of DSM-III-R diagnoses in a national sample of Dutch adolescents. Arch Gen Psychiatry 1997; 54: 329–36

    Article  PubMed  CAS  Google Scholar 

  21. Goldman L, Genel M, Bezman R, et al. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. JAMA 1998; 279: 1100–7

    Article  PubMed  CAS  Google Scholar 

  22. Biederman J. Attention-deficit/hyperactivity disorder: a life-span perspective. J Clin Psychiatry 1998; 59: 4–16

    Article  PubMed  Google Scholar 

  23. Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996; 35: 409–32

    Article  PubMed  CAS  Google Scholar 

  24. Biederman J, Faraone SV, Spencer T, et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1993; 150: 1792–8

    PubMed  CAS  Google Scholar 

  25. Biederman J, Wilens T, Mick E, et al. Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1997; 36: 21–9

    Article  PubMed  CAS  Google Scholar 

  26. Milberger S, Biederman J, Faraone SV, et al. Associations between ADHD and psychoactive substance use disorders: findings from a longitudinal study of high-risk siblings of ADHD children. Am J Addict 1997; 6: 318–29

    PubMed  CAS  Google Scholar 

  27. Milberger S, Biederman J, Faraone SV, et al. Further evidence of an association between attention-deficit/hyperactivity disorder and cigarette smoking: findings from a high-risk sample of siblings. Am J Addict 1997; 6: 205–17

    PubMed  CAS  Google Scholar 

  28. Milberger S, Biederman J, Faraone SV, et al. ADHD is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolesc Psychiatry 1997; 36: 37–44

    Article  PubMed  CAS  Google Scholar 

  29. Milberger S, Biederman J, Faraone SV, et al. Further evidence of an association between maternal smoking during pregnancy and attention deficit hyperactivity disorder: findings from a high-risk sample of siblings. J Clin Child Psychol 1998; 27: 352–8

    Article  PubMed  CAS  Google Scholar 

  30. Leibson C, Katusic S, Barbaresi W, et al. Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA 2001; 285: 60–6

    Article  PubMed  CAS  Google Scholar 

  31. Guevara J, Lozano P, Wickizer T, et al. Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108: 71–8

    Article  PubMed  CAS  Google Scholar 

  32. Bijur P, Golding J, Haslum M, et al. Behavioral predictors of injury in school-age children. Am J Dis Child 1988; 142: 1307–12

    PubMed  CAS  Google Scholar 

  33. Barkley RA, Murphy KR, Kwasnik D. Motor vehicle driving competencies and risks in teens and young adults with attention deficit hyperactivity disorder. Pediatrics 1996; 98: 1089–95

    PubMed  CAS  Google Scholar 

  34. Nader PE. School health: policy and practice. Elk Grove Village (IL): American Academy of Pediatrics, 1993

    Google Scholar 

  35. American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1997; 36: 85–121S

    Article  Google Scholar 

  36. Marchetti A, Magar R, Lau H, et al. Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis. Clin Ther 2001; 23: 1904–21

    Article  PubMed  CAS  Google Scholar 

  37. Connor DF. Aggression and antisocial behavior in children and adolescents: research and treatment. New York: Guilford Press, 2002

    Google Scholar 

  38. DuPaul GJ, Stoner G. ADHD in the schools: assessment and intervention strategies. New York: Guilford Press, 1994

    Google Scholar 

  39. Spencer T, Biederman J, Wilens T. Pharmacotherapy of attention deficit hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2000; 9: 77–97

    PubMed  CAS  Google Scholar 

  40. Elia J, Borcherding B, Rapoport J, et al. Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true non-responders? Psychiatr Res 1991; 36: 141–55

    Article  CAS  Google Scholar 

  41. Greenhill LL, Findling RL, Swanson JM, et al. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2002; 109: e39

    Article  PubMed  Google Scholar 

  42. Multimodal Treatment of ADHD Group. Moderators and mediators of treatment response for children with attention-deficit/ hyperactivity disorder: the multimodal treatment study of children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999; 56: 1088–96

    Article  Google Scholar 

  43. Arnold LE. Methylphenidate vs amphetamine: comparative review. J Atten Disord 2000; 3: 200–11

    Article  Google Scholar 

  44. Greenhill LL, Abikoff H, Arnold LE, et al. Medication treatment strategies in the MTA study: relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry 1996; 35: 1304–13

    Article  PubMed  CAS  Google Scholar 

  45. Gillberg C, Melander H, von Knorring AL, et al. Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997; 54: 857–64

    Article  PubMed  CAS  Google Scholar 

  46. Laufer MW, Denhoff E, Solomons G. Hyperkinetic impulse disorder in children’s behavior problems. Psychosom Med 1957; 19: 38–49

    PubMed  Google Scholar 

  47. Fischer M, Barkley RA, Smallish L, et al. Young adult follow-up of hyperactive children: self-reported psychiatric disorders, comorbidity, and the role of childhood conduct problems and teen CD. J Abnorm Child Psychol 2002; 30: 463–75

    Article  PubMed  Google Scholar 

  48. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 2000; 157: 816–8

    Article  PubMed  CAS  Google Scholar 

  49. Biederman J, Milberger S, Faraone SV, et al. Impact of adversity on functioning and comorbidity in children with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995; 34: 1495–503

    Article  PubMed  CAS  Google Scholar 

  50. Jensen PS. ADHD: current concepts on etiology, pathophysiology, and neurobiology. Child Adolesc Psychiatr Clin N Am 2000; 9: 557–72

    PubMed  CAS  Google Scholar 

  51. Levy F. The dopamine theory of attention deficit hyperactivity disorder (ADHD). Aust N Z J Psychiatry 1991; 25: 277–83

    Article  PubMed  CAS  Google Scholar 

  52. Zametkin A, Liotta W. The neurobiology of attention-deficit/ hyperactivity disorder. J Clin Psychiatry 1998; 59: 17–23

    PubMed  Google Scholar 

  53. Posner MI, Raichle ME. Images of mind. Rev. ed. Washington, DC: Scientific American Books, 1996

    Google Scholar 

  54. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998; 94: 127–52

    Article  PubMed  CAS  Google Scholar 

  55. Wilens TE, Spencer TJ. The stimulants revisited. Child Adolesc Psychiatr Clin N Am 2000; 9: 573–603

    PubMed  CAS  Google Scholar 

  56. Pliszka SR, McCracken JT, Maas JW. Catecholamines in attention-deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry 1996; 35: 264–72

    Article  PubMed  CAS  Google Scholar 

  57. Barkley RA, DuPaul GJ, Connor DF. Stimulants. In: Werry JS, Aman MG, editors. Practitioner’s guide to psychoactive drugs for children and adolescents. New York: Plenum Medical Book Company, 1999: 213–47

    Google Scholar 

  58. Faraone SV, Biederman J. Neurobiology of attention-deficit hyperactivity disorder. Biol Psychiatry 1998; 44: 951–8

    Article  PubMed  CAS  Google Scholar 

  59. Pliszka SR. Neuroscience for the mental health clinician. New York: Guilford Press, 2003: 279

    Google Scholar 

  60. Volkow ND, Ding YS, Fowler JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 1995; 52: 456–63

    Article  PubMed  CAS  Google Scholar 

  61. Wilens TE, Spencer TJ. Pharmacology of amphetamines. In: Tarter RE, Ammerman RT, Ott PJ, editors. Handbook of substance abuse neurobehavioral pharmacology. New York: Plenum Press, 1998: 501–13

    Google Scholar 

  62. Diener RM. Toxicology of ritalin. In: Greenhill LL, Osman BB, editors. Ritalin theory and patient management. New York: Mary Ann Liebert Inc., 1991: 35–43

    Google Scholar 

  63. Pelham WE, Sturges J, Hoza J, et al. Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder. Pediatrics 1987; 80: 491–501

    PubMed  Google Scholar 

  64. Pelham WE, Swanson JM, Furman MB, et al. Pemoline effects on children with ADHD: a time-response by doseresponse analysis on classroom measures. J Am Acad Child Adolesc Psychiatry 1995; 34: 1504–13

    Article  PubMed  Google Scholar 

  65. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. The pharmacological basis of therapeutics. New York: McGraw-Hill, 1996: 199–248

    Google Scholar 

  66. Caldwell J, Sever PS. The biochemical pharmacology of abused drugs. Clin Pharmacol Ther 1974; 16: 625–38

    PubMed  CAS  Google Scholar 

  67. Greenhill LL. Attention deficit hyperactivity disorder: the stimulants. Child Adolesc Psychiatr Clin N Am 1995; 4: 123–68

    Google Scholar 

  68. Birmaher B, Greenhill LL, Cooper TB, et al. Sustained release methylphenidate: pharmacokinetic studies in ADDH males. J Am Acad Child Adolesc Psychiatry 1989; 28: 768–72

    Article  PubMed  CAS  Google Scholar 

  69. Stahl SM. Mirror, mirror on the wall, which enantiomer is fairest of them all? J Clin Psychiatry 2002; 63: 656–7

    Article  PubMed  Google Scholar 

  70. Huang W, Gao Q, Harris M, et al. Separation of ritalin racemate and its by-product racemates by capillary electrophoresis. Electrophoresis 2001; 22: 3226–31

    Article  PubMed  CAS  Google Scholar 

  71. Ferris R, Tang F. Comparison of the effects of the isomers of amphetamine, methylphenidate and deoxypipradol on the uptake of 1-[3H]-norepinephrine and [3H]-dopamine by synaptic vesicles from rat whole brain, striatum and hypothalamus. J Pharmacol Exp Ther 1979; 210: 422–8

    PubMed  CAS  Google Scholar 

  72. Eckerman DA, Moy SS, Perkins AN, et al. Enantioselective behavioral effects of threo-methylphenidate in rats. Pharmacol Biochem Behav 1991; 40: 875–80

    Article  PubMed  CAS  Google Scholar 

  73. Novartis Pharmaceuticals. Focalin product monograph. East Hanover (NJ): Novartis Pharmaceuticals, 2002: 5–19

    Google Scholar 

  74. Ding YS, Fowler JS, Volkow ND, et al. Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and l-threomethylphenidate in the human and baboon brain. Psychopharmacology (Berl) 1997; 131: 71–8

    Article  CAS  Google Scholar 

  75. Srinivas NR, Hubbard JA, Quinn D, et al. Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methyl-phenidate in children with attention deficit disorder. Clin Pharmacol Ther 1992; 52: 561–8

    Article  PubMed  CAS  Google Scholar 

  76. Dexmethylphenidate (Focalin) for ADHD. The Medical Letter 2002; 44(1130): 45–6

    Google Scholar 

  77. Safer DJ, Zito JM, Gardner JF. Pemoline hepatotocxicity and postmarketing surveillance. J Am Acad Child Adolesc Psychiatry 2001; 40: 622–9

    Article  PubMed  CAS  Google Scholar 

  78. McNeil Pharmaceuticals. Concerta product monograph. Fort Washington (PA): 2001: 2-28

  79. ALZA Technologies. Concerta™: a success story [online] Available from URL: http://www.alza.com/pdf/vol_1_1.pdf [Accessed 2004 Oct 1]. Delivery Times 2001; 1 (1)

  80. Data on file, Adderall XR. Shire US Inc., 2001

  81. Novartis Pharmaceuticals. Ritalin LA Product Monograph. East Hanover (NJ): Novartis Pharmaceuticals, 2002

    Google Scholar 

  82. Grcevich S. SLI381: a long-acting psychostimulant preparation for the treatment of attention-deficit hyperactivity disorder. Expert Opin Investig Drugs 2001; 10: 2003–11

    Article  PubMed  CAS  Google Scholar 

  83. Faraone SV, Pliszka SR, Olvera RL, et al. Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a reanalysis using drug-placebo and drug-drug response curve methodology. J Child Adolesc Psychopharmacol 2001; 11: 171–80

    Article  PubMed  CAS  Google Scholar 

  84. Keating GM, McClellan K, Jarvis B. Methylphenidate (OROS Formulation). CNS Drugs 2001; 15: 495–500

    Article  PubMed  CAS  Google Scholar 

  85. Auiler JF, Liu JM, Lynch JM, et al. Effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR food evaluation (CAFE) study. Curr Med Res Opin 2002; 18: 311–6

    Article  PubMed  CAS  Google Scholar 

  86. Pentikis HS, Simmons RD, Benedict MF, et al. Methylphenidate bioavailability in adults when an extended-release multiparticulate formulation is administered sprinkled on food or as an intact capsule. J Am Acad Child Adolesc Psychiatry 2002; 41: 443–9

    Article  PubMed  Google Scholar 

  87. Michaels MA, Weston IE, Zhang Y, et al. Pharmacokinetics of SLI381, a two-component extended-release formulation of mixed amphetamine salts, administered in fasted and fed states, and sprinkled on food. Phoenix (AZ): New Clinical Drug Evaluation Unit, 2001 May 29

    Google Scholar 

  88. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001; 107: 1–15

    Article  Google Scholar 

  89. Wolraich ML, Greenhill LL, Pelham WE, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108: 883–92

    Article  PubMed  CAS  Google Scholar 

  90. Swanson JM, Wigal SB, Lerner MA, et al. Comparison of the efficacy and safety of OROS methylphenidate HCL with methylphenidate tid and placebo in children with ADHD [abstract]. Pediatr Res 2000; 47: 199

    Google Scholar 

  91. Wilens T, Pelham WE, Stein MT, et al. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 2003; 42: 424–33

    Article  PubMed  Google Scholar 

  92. McCracken JT, McGough JJ, Biederman J, et al. Analogue classroom assessment of SLI381 for the treatment of ADHD [presentation]. 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; 2000 Oct, New York

  93. Biederman J, Lopez F, Boellner S, et al. A randomized, doubleblind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics 2002; 110: 258–66

    Article  PubMed  Google Scholar 

  94. Biederman J, Lopez F, Boellner S, et al. A randomized controlled trial of once-daily-dosed Adderall XR for the treatment of ADHD. Boston (MA): US Psychiatric and Mental Health Congress, 2001 Nov

    Google Scholar 

  95. Ambrosini PJ, Lopez F, Chandler M, et al. An open-label community assessment trial of Adderall XR in pediatric ADHD [presentation]. 155th Annual Meeting of the American Psychiatric Association; Philadelphia (PA); 2002 May 22

  96. Celltech Development. Protocol No. 1001-02. Wayne (PA): Celltech Development, 2002

  97. Boellner S, Tulloch SJ, Zhang Y. A single-dose bioequivalence study comparing 1 × 30mg capsule of SLI 381 to 3 × 10mg capsules of SLI 381 in pediatric subjects. Phoenix (AZ): New Clinical Drug Evaluation Unit, 2002 May 29

    Google Scholar 

  98. Swanson JM, Greenhill LL, Pelham WE, et al. Initiating Concerta (OROS methylphenidate HCL) qd in children with attention-deficit/hyperactivity disorder. J Clin Res 2000; 3: 59–76

    Google Scholar 

  99. James RS, Sharp WS, Bastain TM, et al. Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD. J Am Acad Child Adolesc Psychiatry 2001; 40: 1268–76

    Article  PubMed  CAS  Google Scholar 

  100. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/ hyperactivity disorder: a randomized, placebo-controlled, dose response study. Pediatrics 2001; 108: 1–9

    Article  Google Scholar 

  101. Wilens TE, Biederman J, Mick E, et al. Attention deficit hyperactivity disorder (ADHD) is associated with early onset substance use disorders. J Nerv Ment Dis 1997; 185: 475–82

    Article  PubMed  CAS  Google Scholar 

  102. Barkley RA, Fischer M, Smallish L, et al. Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug abuse? A 13-year prospective study. Pediatrics 2003; 111: 97–109

    Article  PubMed  Google Scholar 

  103. Wilens TE, Faraone SV, Biederman J, et al. Does stimulant therapy of attention deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003; 11: 179–85

    Article  Google Scholar 

  104. Wilens TE, Biederman J, Mick E. Does ADHD affect the course of substance abuse? Findings from a sample of adults with and without ADHD. Am J Addict 1998; 7: 156–63

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Dr Connor serves on the ADHD Expert Advisory Board and the ADHD Speaker’s Bureau for Shire, US, Inc. and Eli Lilly, the ADHD Speaker’s Bureau for Johnson-McNeil Pharmaceuticals, and has participated in funded research sponsored by Shire, US, Inc., Eli Lilly, GlaxoSmithKline, Cephalon, and Novartis Pharmaceuticals. Dr Steingard has participated in funded research sponsored by Shire, US, Inc., and GlaxoSmithKline Pharmaceuticals. No sources of funding were used to assist in the preparation of this review.

Author information

Authors and Affiliations

  1. Department of Psychiatry, Division of Child and Adolescent Psychiatry, University of Massachusetts Medical School, 7th Floor, Room S7-850, 55 Lake Avenue North, Worcester, Massachusetts, 01655, USA

    Daniel F. Connor & Ronald J. Steingard

Authors
  1. Daniel F. Connor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ronald J. Steingard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel F. Connor.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Connor, D.F., Steingard, R.J. New Formulations of Stimulants for Attention-Deficit Hyperactivity Disorder. CNS Drugs 18, 1011–1030 (2004). https://doi.org/10.2165/00023210-200418140-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200418140-00005

Keywords

Search

Navigation